查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401897

到 2030 年液体活检市场预测：按产品和服务、样本类型、技术、循环生物标记、癌症、临床应用、最终用户和地区进行的全球分析

Liquid Biopsy Market Forecasts to 2030 - Global Analysis By Product & Services, By Type of Sample, Technology, Circulating Biomarker, Cancer, Clinical Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC预测，2023年全球液体切片市场规模将达51亿美元，预计2030年将达到188亿美元，预测期内复合年增长率为20.3%。

液体活检是一种非侵入性医学测试，可检测血液和尿液等体液中的循环肿瘤 DNA (ctDNA)、RNA 和蛋白质等生物标记。液体活检透过识别与疾病相关的基因突变和变化来深入了解患者的健康状况，特别是在癌症诊断中。液体活检提供了一种微创方法来监测和分析分子变化，以实现早期检测、治疗效果评估和个人化医疗。这种创新方法彻底改变了癌症诊断和监测，提供了个人健康状况的动态、即时观点。

根据国际癌症研究机构的数据，最常见的癌症类型是肺癌、乳癌、摄护腺癌和大肠。据估计，2020年至2040年，全球癌症患者人数将增加47%，2040年全球癌症患者人数将达2,840万人。

全球癌症盛行率不断上升

全球癌症发生率上升是液体切片市场的关键驱动因素。随着全球癌症发生率的增加，对有效、非侵入性诊断工具的需求日益增长。液体活检透过提供一种微创的癌症检测和监测方法来满足这一需求。液体活检可以实现早期检测、客製化治疗以及即时监测治疗反应。此外，液体活检逐渐被认为是对抗癌症的宝贵工具，也是解决全球范围内日益增长的癌症负担的关键组成部分。

敏感性和特异性挑战

这些测试在准确检测或排除特定病理的表现参差不齐，引发了人们对其可靠性的担忧。实现高灵敏度对于临床效用至关重要。不一致的结果可能导致假阳性或假阴性，影响整体液体活检的准确性，从而阻碍整体市场的成长。

政府对卫生基础建设的投资

增加的资金将加强研发并支持液体活检技术的技术进步和创新。基础设施的改善将改善诊断服务的可近性，并促进液体切片检查的引入以早期发现癌症。政府的支持也将促进液体切片检查纳入主流医疗系统并使其广泛使用。这与公共卫生配合措施一致，并为市场成长创造了有利的环境。

严格的监管要求以及与传统切片检查方法的竞争

严格的监管要求对液体切片检查市场构成威胁，可能会延迟产品核准和市场进入。满足这些监管要求需要大量的资源和时间。此外，市场还面临来自成熟的传统切片检查方法的竞争，导致怀疑和采用缓慢。医生和医疗机构可能更喜欢熟悉的传统方法，这阻碍了液体活检技术的快速整合。

COVID-19 的影响：

COVID-19大流行对液体活检市场产生了重大影响。医疗保健系统和优先事项的中断转移了非必要诊断的注意力和资源，从而减缓了市场成长。然而，这场大流行凸显了非侵入性和远距离诊断的重要性，并激发了人们对液体活检技术的兴趣。最大限度地减少患者接触和加快诊断过程的需求加速了液体活检的采用，特别是在肿瘤学领域，并且它们对大流行带来的医疗保健挑战的潜在弹性和适应能力已得到证明。

预计在预测期内血液部分将是最大的

在预测期内，血液领域预计将主导液体活检市场并获得最大的市场占有率。这一优势归因于对非侵入性癌症诊断的需求不断增长以及血液采样的便利性。利用循环肿瘤 DNA (ctDNA) 和其他生物标记的血液液体活检有助于早期癌症检测和治疗监测。此外，次世代定序仪定序等高通量技术的进步提高了分子分析的精确度，进一步支持了该领域的成长。

前列腺癌细分市场预计在预测期内复合年增长率最高

在预测期内，前列腺癌领域的液体活检市场预计将出现无与伦比的成长。这种快速增长是由于对前列腺癌（通常无症状）的准确和微创诊断解决方案的迫切需求所推动的。液体活检透过简单的抽血检测循环肿瘤 DNA (ctDNA) 和其他生物标记物，为前列腺癌的诊断和监测提供了革命性的方法。此外，液体活检技术的进步，加上对个人化医疗日益增长的兴趣，使前列腺癌领域处于市场扩张的前沿。

占有率最大的地区

预计在预测期内，北美将占据液体活检市场的最大市场占有率。这项优势得益于完善的医疗基础设施、加大的研发投入以及较高的癌症发生率等因素。此外，该地区还受益于先进医疗技术的早期采用和对个人化医疗的重视。此外，主要市场参与企业的存在和有利的政府配合措施使北美处于液体活检市场的前沿。

复合年增长率最高的地区：

亚太地区是预测期间液体切片市场复合年增长率最高的地区。原因包括癌症发生率上升、医疗基础设施改善以及先进诊断技术的采用增加。该地区人口众多且多样化，加上政府加强卫生服务的配合措施，正在推动对非侵入性癌症诊断的需求。此外，国际和本地公司之间的合作以及对精准医疗日益增长的兴趣进一步支持了亚太地区液体活检市场的扩张。

免费客製化服务

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 最终用户分析
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球液体活检市场：按产品和服务分类

  • 介绍
  • 套件和试剂
  • 平台及装置
  • 服务

第六章全球液体切片市场：依样本类型

  • 介绍
  • 血
  • 唾液
  • 尿
  • 其他类型样品

第七章全球液体切片市场：依技术分类

  • 介绍
  • 使用 NGS 并行分析多个基因
  • 使用 PCR 微阵列进行单基因分析

第八章全球液体活检市场：透过循环生物标记

  • 介绍
  • 游离 DNA (cfDNA)
  • 循环性肿瘤细胞
  • 循环肿瘤 DNA (ctDNA)
  • 细胞外囊泡（EVS）
  • 其他循环生物标记

第九章全球液体切片市场：依癌症分类

  • 介绍
  • 乳癌
  • 大肠直肠癌
  • 肝癌
  • 肺癌
  • 摄护腺癌
  • 其他癌症

第十章全球液体切片市场：依临床应用

  • 介绍
  • 早期癌症筛检
  • 復发监测
  • 治疗方法选择
  • 治疗监测
  • 其他临床应用

第十一章全球液体活检市场：按最终用户分类

  • 介绍
  • 门诊手术中心
  • 诊断实验室
  • 医院和诊所
  • 製药和生物技术公司
  • 研究机构
  • 其他最终用户

第十章全球液体切片市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • ANGLE plc
  • Biocept Inc.
  • Bio-Rad Laboratories
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd.
  • Freenome Holdings, Inc.
  • Guardant Health
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Johnson & Johnson
  • Laboratory Corporation of America Holdings
  • Lucence Health Inc.
  • MDxHealth SA
  • Myriad Genetics, Inc.
  • Oncimmune
  • QIAGEN NV
  • Thermo Fisher Scientific Inc
Product Code: SMRC24417

According to Stratistics MRC, the Global Liquid Biopsy Market is accounted for $5.1 billion in 2023 and is expected to reach $18.8 billion by 2030 growing at a CAGR of 20.3% during the forecast period. Liquid biopsy is a non-invasive medical test that detects biomarkers, such as circulating tumor DNA (ctDNA), RNA, and proteins, in bodily fluids like blood or urine. It provides insights into a patient's health, particularly in cancer diagnostics, by identifying genetic mutations or alterations associated with the disease. Liquid biopsy offers a less invasive method to monitor and analyze molecular changes, aiding in early detection, treatment response assessment, and personalized medicine. This innovative approach revolutionizes cancer diagnostics and monitoring, offering a dynamic and real-time perspective on an individual's health status.

According to the International Agency for Research on Cancer, the most prevalent types of cancer includes lungs cancer, breast cancer, prostate cancer, and colorectal cancer. The cancer cases across the globe is estimated to rise by 47% from 2020 to 2040, and the number of cancer cases are estimated to be 28.4 million by 2040 across the globe.

Market Dynamics:

Driver:

Increasing prevalence of cancer globally

The escalating global prevalence of cancer serves as a significant driver for the liquid biopsy market. As cancer incidence rises worldwide, there is a growing need for effective and non-invasive diagnostic tools. Liquid biopsies, offering a minimally invasive approach to detecting and monitoring cancers, meet this demand. They enable early detection, treatment customization, and real-time monitoring of therapeutic responses. Moreover, the increasing recognition of liquid biopsies as valuable tools in the fight against cancer positions them as a crucial component in addressing the rising burden of this disease on a global scale.

Restraint:

Sensitivity and specificity challenges

The variable performance of these tests in terms of accurately detecting and ruling out specific conditions raises concerns about their reliability. Achieving high sensitivity is crucial for clinical utility. Inconsistent results may lead to false positives or negatives, impacting the overall accuracy of liquid biopsy and thereby hindering overall market growth.

Opportunity:

Government investments on healthcare infrastructure

Increased funding enhances research and development, aiding technological advancements and innovation in liquid biopsy technologies. Improved infrastructure fosters better accessibility to diagnostic services, promoting the adoption of liquid biopsy for early cancer detection. Government support can also facilitate the integration of liquid biopsy into mainstream healthcare systems, ensuring widespread availability. This aligns with public health initiatives, creating a conducive environment for market growth.

Threat:

Stringent regulatory requirements and competition with traditional biopsy methods

Stringent regulatory requirements pose a threat to the liquid biopsy market by potentially slowing down product approvals and market entry. Meeting these requirements demands substantial resources and time. Additionally, the market faces competition from well-established traditional biopsy methods, leading to skepticism and slower adoption. Physicians and healthcare institutions may prefer conventional approaches they are familiar with, hindering the rapid integration of liquid biopsy techniques.

COVID-19 Impact:

The COVID-19 pandemic had a significant effect on the liquid biopsy market. Disruptions in healthcare systems and priorities diverted attention and resources away from non-essential diagnostics, slowing market growth. However, the pandemic underscored the importance of non-invasive and remote diagnostics, fueling interest in liquid biopsy technologies. The need for minimizing patient contact and expediting diagnostic processes accelerated the adoption of liquid biopsies, especially in oncology, demonstrating their potential resilience and adaptability in response to healthcare challenges posed by the pandemic.

The blood segment is expected to be the largest during the forecast period

Over the forecast period, the blood segment is poised to dominate the liquid biopsy market, securing the largest market share. This dominance is attributed to the escalating demand for non-invasive cancer diagnostics and the convenience of obtaining blood samples. Blood-based liquid biopsies, leveraging circulating tumor DNA (ctDNA) and other biomarkers, facilitate early cancer detection and treatment monitoring. Additionally, the segment's growth is further propelled by advancements in high-throughput technologies like next-generation sequencing, which enhance the precision of molecular analysis.

The prostate cancer segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the prostate cancer segment is expected to witness unparalleled growth in the liquid biopsy market. This surge is driven by the pressing need for accurate and minimally invasive diagnostic solutions for prostate cancer, a prevalent and often asymptomatic condition. Liquid biopsy's ability to detect circulating tumor DNA (ctDNA) and other biomarkers from a simple blood draw offers a revolutionary approach to prostate cancer diagnosis and monitoring. Moreover, advancements in liquid biopsy technologies, coupled with a growing emphasis on personalized medicine, position the prostate cancer segment at the forefront of the market's expansion.

Region with largest share:

North America is anticipated to command the largest market share during the forecast period in the liquid biopsy market. This dominance is attributed to factors such as a well-established healthcare infrastructure, increased investment in research and development, and a high prevalence of cancer. Moreover, the region benefits from the early adoption of advanced medical technologies and a strong emphasis on personalized medicine. Additionally, the presence of key market players, coupled with favorable government initiatives, positions North America at the forefront of the liquid biopsy market.

Region with highest CAGR:

The Asia Pacific region is positioned to experience the highest CAGR during the forecast period in the liquid biopsy market. Owing to the rising incidence of cancer, improving healthcare infrastructure, and increasing adoption of advanced diagnostic technologies. The region's large and diverse population, coupled with government initiatives to enhance healthcare services, fosters the demand for non-invasive cancer diagnostics. Additionally, collaborations between international and local companies, along with a growing focus on precision medicine, further drive the expansion of the liquid biopsy market in the Asia Pacific region.

Key players in the market:

Some of the key players in Liquid Biopsy Market include ANGLE plc, Biocept Inc., Bio-Rad Laboratories, Epigenomics AG, F. Hoffmann-La Roche Ltd., Freenome Holdings, Inc., Guardant Health, Inc., Illumina, Inc., Johnson & Johnson Laboratory Corporation of America Holdings, Lucence Health Inc., MDxHealth SA, Myriad Genetics, Inc., Oncimmune, QIAGEN N.V and Thermo Fisher Scientific Inc.

Key Developments:

In November 2023, ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, is delighted to announce the launch of its Portrait® PD-L1 test for the evaluation of PD-L1 protein expression on CTCs following extensive development and optimisation. The test is provided as a service from ANGLE's Onc-ADaPT® GCP-compliant laboratories and is conducted by an expert team with over 10 years' experience in CTC analysis.

In March 2023, ANGLE plc, a world-leading liquid biopsy company, is delighted to announce that its first bespoke assay development customer, Artios Pharma (Artios), has signed a new contract to utilise two DNA Damage Response assays developed by ANGLE in a Phase 1 clinical trial expected to commence short.

Product & Services Covered:

  • Kits & Reagents
  • Platforms & Instruments
  • Services

Type of Samples Covered:

  • Blood
  • Saliva
  • Urine
  • Other Types of Samples

Technologies Covered:

  • Multi-gene Parallel Analysis using NGS
  • Single-gene Analysis using PCR Microarrays

Circulating Biomarkers Covered:

  • Cell-free DNA (cfDNA)
  • Circulating Tumor Cells
  • Circulating Tumor DNA (ctDNA)
  • Extracellular Vesicles (EVS)
  • Other Circulating Biomarkers

Cancers Covered:

  • Breast Cancer
  • Colorectal Cancer
  • Liver Cancer
  • Lung Cancer
  • Prostate Cancer
  • Other Cancers

Clinical Applications Covered:

  • Early Cancer Screening
  • Recurrence Monitoring
  • Therapy Selection
  • Treatment Monitoring
  • Other Clinical Applications

End Users Covered:

  • Ambulatory Surgical Centers
  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Pharmaceutical and Biotechnology Companies
  • Research Institutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Liquid Biopsy Market, By Product & Services

  • 5.1 Introduction
  • 5.2 Kits & Reagents
  • 5.3 Platforms & Instruments
  • 5.4 Services

6 Global Liquid Biopsy Market, By Type of Sample

  • 6.1 Introduction
  • 6.2 Blood
  • 6.3 Saliva
  • 6.4 Urine
  • 6.5 Other Types of Samples

7 Global Liquid Biopsy Market, By Technology

  • 7.1 Introduction
  • 7.2 Multi-gene Parallel Analysis using NGS
  • 7.3 Single-gene Analysis using PCR Microarrays

8 Global Liquid Biopsy Market, By Circulating Biomarker

  • 8.1 Introduction
  • 8.2 Cell-free DNA (cfDNA)
  • 8.3 Circulating Tumor Cells
  • 8.4 Circulating Tumor DNA (ctDNA)
  • 8.5 Extracellular Vesicles (EVS)
  • 8.6 Other Circulating Biomarkers

9 Global Liquid Biopsy Market, By Cancer

  • 9.1 Introduction
  • 9.2 Breast Cancer
  • 9.3 Colorectal Cancer
  • 9.4 Liver Cancer
  • 9.5 Lung Cancer
  • 9.6 Prostate Cancer
  • 9.7 Other Cancers

10 Global Liquid Biopsy Market, By Clinical Application

  • 10.1 Introduction
  • 10.2 Early Cancer Screening
  • 10.3 Recurrence Monitoring
  • 10.4 Therapy Selection
  • 10.5 Treatment Monitoring
  • 10.6 Other Clinical Applications

11 Global Liquid Biopsy Market, By End User

  • 11.1 Introduction
  • 11.2 Ambulatory Surgical Centers
  • 11.3 Diagnostic Laboratories
  • 11.4 Hospitals and Clinics
  • 11.5 Pharmaceutical and Biotechnology Companies
  • 11.6 Research Institutions
  • 11.7 Other End Users

10 Global Liquid Biopsy Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 ANGLE plc
  • 12.2 Biocept Inc.
  • 12.3 Bio-Rad Laboratories
  • 12.4 Epigenomics AG
  • 12.5 F. Hoffmann-La Roche Ltd.
  • 12.6 Freenome Holdings, Inc.
  • 12.7 Guardant Health
  • 12.8 Guardant Health, Inc.
  • 12.9 Illumina, Inc.
  • 12.10 Johnson & Johnson
  • 12.11 Laboratory Corporation of America Holdings
  • 12.12 Lucence Health Inc.
  • 12.13 MDxHealth SA
  • 12.14 Myriad Genetics, Inc.
  • 12.15 Oncimmune
  • 12.16 QIAGEN N.V
  • 12.17 Thermo Fisher Scientific Inc

List of Tables

  • Table 1 Global Liquid Biopsy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Liquid Biopsy Market Outlook, By Product & Services (2021-2030) ($MN)
  • Table 3 Global Liquid Biopsy Market Outlook, By Kits & Reagents (2021-2030) ($MN)
  • Table 4 Global Liquid Biopsy Market Outlook, By Platforms & Instruments (2021-2030) ($MN)
  • Table 5 Global Liquid Biopsy Market Outlook, By Services (2021-2030) ($MN)
  • Table 6 Global Liquid Biopsy Market Outlook, By Type of Sample (2021-2030) ($MN)
  • Table 7 Global Liquid Biopsy Market Outlook, By Blood (2021-2030) ($MN)
  • Table 8 Global Liquid Biopsy Market Outlook, By Saliva (2021-2030) ($MN)
  • Table 9 Global Liquid Biopsy Market Outlook, By Urine (2021-2030) ($MN)
  • Table 10 Global Liquid Biopsy Market Outlook, By Other Types of Samples (2021-2030) ($MN)
  • Table 11 Global Liquid Biopsy Market Outlook, By Technology (2021-2030) ($MN)
  • Table 12 Global Liquid Biopsy Market Outlook, By Multi-gene Parallel Analysis using NGS (2021-2030) ($MN)
  • Table 13 Global Liquid Biopsy Market Outlook, By Single-gene Analysis using PCR Microarrays (2021-2030) ($MN)
  • Table 14 Global Liquid Biopsy Market Outlook, By Circulating Biomarker (2021-2030) ($MN)
  • Table 15 Global Liquid Biopsy Market Outlook, By Cell-free DNA (cfDNA) (2021-2030) ($MN)
  • Table 16 Global Liquid Biopsy Market Outlook, By Circulating Tumor Cells (2021-2030) ($MN)
  • Table 17 Global Liquid Biopsy Market Outlook, By Circulating Tumor DNA (ctDNA) (2021-2030) ($MN)
  • Table 18 Global Liquid Biopsy Market Outlook, By Extracellular Vesicles (EVS) (2021-2030) ($MN)
  • Table 19 Global Liquid Biopsy Market Outlook, By Other Circulating Biomarkers (2021-2030) ($MN)
  • Table 20 Global Liquid Biopsy Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 21 Global Liquid Biopsy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 22 Global Liquid Biopsy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 23 Global Liquid Biopsy Market Outlook, By Liver Cancer (2021-2030) ($MN)
  • Table 24 Global Liquid Biopsy Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 25 Global Liquid Biopsy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 26 Global Liquid Biopsy Market Outlook, By Other Cancers (2021-2030) ($MN)
  • Table 27 Global Liquid Biopsy Market Outlook, By Clinical Application (2021-2030) ($MN)
  • Table 28 Global Liquid Biopsy Market Outlook, By Early Cancer Screening (2021-2030) ($MN)
  • Table 29 Global Liquid Biopsy Market Outlook, By Recurrence Monitoring (2021-2030) ($MN)
  • Table 30 Global Liquid Biopsy Market Outlook, By Therapy Selection (2021-2030) ($MN)
  • Table 31 Global Liquid Biopsy Market Outlook, By Treatment Monitoring (2021-2030) ($MN)
  • Table 32 Global Liquid Biopsy Market Outlook, By Other Clinical Applications (2021-2030) ($MN)
  • Table 33 Global Liquid Biopsy Market Outlook, By End User (2021-2030) ($MN)
  • Table 34 Global Liquid Biopsy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 35 Global Liquid Biopsy Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 36 Global Liquid Biopsy Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 37 Global Liquid Biopsy Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 38 Global Liquid Biopsy Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 39 Global Liquid Biopsy Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.